103.64p+0.64 (+0.62%)19 Apr 2024, 13:13
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Diaceutics PLC Fundamentals

Company NameDiaceutics PLCLast Updated2024-04-19
IndustryDiagnostics & ResearchSectorHealthcare
Shares in Issue84.679 mMarket Cap£87.76 m
PE Ratio129.87Dividend per Share0
Dividend Yield0Dividend Cover0
EPS£0.01EPS Growth (%)0.28
PEG0DPS Growth (%)0
Debt Ratio0.0273Debt Equity Ratio0.0276
Asset Equity Ratio1.1233Cash Equity Ratio0.4355
Quick Ratio7.4750Current Ratio7.99
Price To Book Value2.1240ROCE0

Diaceutics PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Diaceutics PLC Company Financials

Assets20222021
Tangible Assets£2.09 m£2.13 m
Intangible Assets£15.22 m£12.82 m
Investments00
Total Fixed Assets£17.36 m£14.95 m
Stocks00
Debtors£8.58 m£7.15 m
Cash & Equivalents£19.84 m£19.68 m
Other Assets00
Total Assets£48.26 m£45.01 m
Liabilities20222021
Creditors within 1 year£3.75 m£2.63 m
Creditors after 1 year£1.99 m£1.73 m
Other Liabilities00
Total Liabilities£5.74 m£4.36 m
Net assets£42.51 m£40.65 m
Equity20222021
Called up share capital£169,000.00£168,000.00
Share Premium£37.13 m£36.86 m
Profit / Loss£564,000.00£462,000.00
Other Equity£42.51 m£40.65 m
Preference & Minorities00
Total Capital Employed£42.51 m£40.65 m
Ratios20222021
Debt Ratio£0.03£0.03
Debt-to-Equity£0.03£0.03
Assets / Equity1.12331.1233
Cash / Equity0.43550.4355
EPS£0.01£0.01
Cash Flow20222021
Cash from operating activities£5.10 m£570,000.00
Cashflow before financing£4.91 m£300,000.00
Increase in Cash£146,000.00-£5.30 m
Income20222021
Turnover£19.50 m£13.94 m
Cost of sales£2.76 m£1.71 m
Gross Profit£16.74 m£12.23 m
Operating Profit£575,000.00£550,000.00
Pre-Tax profit£564,000.00£462,000.00

Diaceutics PLC Company Background

SectorHealthcare
ActivitiesDiaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides the pharma and biotech companies with an end-to-end commercialization solution for the launch of precision medicine, enabled by DXRX The Diagnostic Network. DXRX is the diagnostic commercialization platform designed specifically for precision medicine, integrating multiple pipelines of real-world, real-time diagnostic testing data from a network of labs. These solutions are helping the pharma companies commercialize their precision medicines, enhance their return on investment and ultimately improve patients' lives.
Latest Interim Date26 Sep 2023
Latest Fiscal Year End Date17 Apr 2023

Diaceutics PLC Directors

AppointedNamePosition
2023-04-25Mr. Michael Wort Non-Executive Director
2023-04-25Mr. Charles Hindson Non-Executive Director
2024-03-07Mr. Graham Douglas PattersonNon-Executive Director
2023-04-25Ms. Deborah Lee DavisNon-Executive Director,Chairman
2020-12-22Ms. Julie Goonewardene Wallin Non-Executive Director,Chairman
2024-04-02Mr. Peter KeelingExecutive Director
2023-05-19Mr. Ryan Keeling Executive Director,Chief Executive Officer
2022-03-18Mr. Philip White FCAExecutive Director,Chief Financial Officer
2024-04-03Mr. Nicholas Stewart RobertsExecutive Director,Chief Financial Officer

Diaceutics PLC Contact Details

Company NameDiaceutics PLC
Address55-59 Adelaide Street, Titanic Suites, Enterprise House, Antrim, BT2 8FE
Telephone
Websitehttps://www.diaceutics.com

Diaceutics PLC Advisors